Currently Viewing:
North American Neuroendocrine Tumor Society Symposium 2018
Dr Thorvardur Halfdanarson on Diagnostics in NETs
November 08, 2018
Currently Reading
Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs
November 06, 2018
Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs
October 23, 2018
Dr Scott Paulson on Standard of Treatment, Novel Approaches Being Taken in GEP-NETs
October 19, 2018
Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs
October 17, 2018
Research at NANETS Cites Value of Genetic Testing in Neuroendocrine Tumors
October 07, 2018
A Comprehensive Look at Updates, Developments in NETs
October 07, 2018
An Update on Lung NET Guidelines
October 07, 2018
Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs
October 07, 2018
Sequencing of Lanreotide Can Improve Outcomes in Patients With Advanced GEP-NETs
October 06, 2018
Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape
October 06, 2018
Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options
October 06, 2018
Debating Best First-Line Treatment in Well-Differentiated G3 NENs
October 06, 2018
Examining the Benefits of Integrative Oncology, Nutrition in NETs
October 05, 2018
Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs
October 05, 2018
Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs
October 05, 2018
Measuring Quality of Life Among Patients With Neuroendocrine Tumors
October 05, 2018

Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs

Somatostatins have been the most game-changing drug in the treatment landscape of gastroenteropancreatic neuroendocrine tumors, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.


Somatostatins have been the most game-changing drug in the treatment landscape of gastroenteropancreatic neuroendocrine tumors, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.

Transcript

What role do somatostatin analogs play in the treatment of gastroenteropancreatic neuroendocrine tumors?

I’d say it’s probably the most central pharmaceutical in the treatment of these tumors. I think it’s probably been the most game-changing drug as far as the landscape’s concerned, over the last 20 years. They’re fairly low toxicity drugs. Their biggest toxicity is really that they’re costly and they’re monthly, so they require a little more effort out of the patients and that they’re going to have to continue to come in for monthly injections. But, they’re still going to be the most central pharmacologic agent and, often time, our best tool in the toolbelt, if you will.

Are there any patient characteristics or biomarkers that indicate response to treatment?

So, there’s a lot of things that are being looked at. Centrally, I think imaging is playing a bigger and bigger role, even in the community-based setting. So, things like DOTATATE PET/CT, 68Ga-DOTATATE PET/CT, has really changed the way that we look at it because you can get a much more comprehensive biomarker of the entire tumor by dong some nuclear imaging, and that gives you an idea of what receptors light up and what drugs you may be able to use and is an appropriate indicator of how well things like peptide receptor radionuclide therapy (PRRT) will work.

Whether it’s a really appropriate indicator of how well things like somatostatin analogs will work is still a little matter of debate. That evidence is not nearly as robust. But, that gives you a pretty good comprehensive picture of the tumor. There has been a lot of look at SSTR2A, which is a marker on the outside of the cells that they can stain for pathologically and how that’s being linked for responses to therapies is certainly being used as criteria for a couple of clinical trials at hand.

And then, the biggest indicators are classically what we’ve always used to just grade these things pathologically, which is what do they look like under a microscope, how aggressive do they look, what is the Ki-67, which continues to be an extremely useful prognostic tool. Those types of factors are still, I would say, the most central things that we use to try and make treatment decisions up front.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!